Search Results - "Pannus, P."

Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment by Peeters, M., Verbruggen, L., Teuwen, L., Vanhoutte, G., Vande Kerckhove, S., Peeters, B., Raats, S., Van der Massen, I., De Keersmaecker, S., Debie, Y., Huizing, M., Pannus, P., Neven, K., Ariën, K.K., Martens, G.A., Van Den Bulcke, M., Roelant, E., Desombere, I., Anguille, S., Goossens, M., Vandamme, T., van Dam, P.

“…Cancer patients are at a higher risk of developing severe coronavirus disease 2019 (COVID-19). However, the safety and efficacy of COVID-19 vaccination in…”
Get full text

O7 Does viral suppressive capacity in cART-treated HIV-infected patients correlate with disease parameters, viral reservoir measures or cytotoxic T cell phenotype? by P. Pannus, P. Adams, E. Willems, L. Heyndrickx, M. Van Frankenhuijsen, E. Florence, M. Kiselinova, S. Rutsaert, K. Vervisch, W. Despiegelaere, C. Devaux, L. Vandekerckhove, G. Vanham

Get full text